About Avalyn Pharma
Avalyn Pharma is a company based in Seattle (United States) founded in 2011.. Avalyn Pharma has raised $388.86 million across 6 funding rounds from investors including TPG, Citadel and Edmond de Rothschild. Avalyn Pharma offers products and services including AP01, AP02, and AP03. Avalyn Pharma operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Seattle, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Avalyn Pharma Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$388.86 M (USD)
in 6 rounds
-
Latest Funding Round
$100 M (USD), Series D
Jul 22, 2025
-
Investors
TPG
& 19 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Avalyn Pharma
Avalyn Pharma offers a comprehensive portfolio of products and services, including AP01, AP02, and AP03. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhaled pirfenidone for treating pulmonary fibrosis.
Inhaled nintedanib for respiratory disease management.
Fixed-dose combination of pirfenidone and nintedanib for lung conditions.
Unlock access to complete
Unlock access to complete
Funding Insights of Avalyn Pharma
Avalyn Pharma has successfully raised a total of $388.86M across 6 strategic funding rounds. The most recent funding activity was a Series D round of $100 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series D — $100.0M
-
First Round
First Round
(11 Aug 2015)
- Investors Count 20
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2025 | Amount | Series D - Avalyn Pharma | Valuation | Suvretta Capital Management , SR One | |
| Sep, 2023 | Amount | Series C - Avalyn Pharma | Valuation | Perceptive Advisors , Xontogeny | |
| Apr, 2020 | Amount | Series B - Avalyn Pharma | Valuation | Norwest Venture Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Avalyn Pharma
Avalyn Pharma has secured backing from 20 investors, including venture fund and institutional investors. Prominent investors backing the company include TPG, Citadel and Edmond de Rothschild. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Life science startups are accelerated through focused programs by Xontogeny.
|
Founded Year | Domain | Location | |
|
A biotechnology venture capital firm investing in innovative science.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Avalyn Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Avalyn Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Avalyn Pharma Comparisons
Competitors of Avalyn Pharma
Avalyn Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
Dental implants and regenerative dentistry products are developed.
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Avalyn Pharma
Frequently Asked Questions about Avalyn Pharma
When was Avalyn Pharma founded?
Avalyn Pharma was founded in 2011 and raised its 1st funding round 4 years after it was founded.
Where is Avalyn Pharma located?
Avalyn Pharma is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Is Avalyn Pharma a funded company?
Avalyn Pharma is a funded company, having raised a total of $388.86M across 6 funding rounds to date. The company's 1st funding round was a Series B of $35.5M, raised on Aug 11, 2015.
What does Avalyn Pharma do?
Avalyn Pharma was founded in 2011 in Seattle, United States, within the biotechnology sector. Inhaled therapies for Idiopathic Pulmonary Fibrosis are developed, with the lead program Aerodone featuring a pirfenidone formulation for direct lung delivery. Operations focus on advancing treatments for this lung condition. Orphan-drug designation has been granted by the FDA for the pirfenidone application.
Who are the top competitors of Avalyn Pharma?
Avalyn Pharma's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
What products or services does Avalyn Pharma offer?
Avalyn Pharma offers AP01, AP02, and AP03.
Who are Avalyn Pharma's investors?
Avalyn Pharma has 20 investors. Key investors include TPG, Citadel, Edmond de Rothschild, Piper Sandler, and Norwest Venture Partners.